RecruitingNCT06735612

Respiratory Syncytial Virus Infection in Exacerbations of Chronic Obstructive Pulmonary Diasease: the RECODE Study


Sponsor

Fundacio Privada Mon Clinic Barcelona

Enrollment

892 participants

Start Date

Dec 16, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to determine the prevalence of respiratory syncytial virus (RSV) infection and evaluate its association with clinical outcomes in patients with chronic obstructive pulmonary disease (COPD) who experience exacerbations during the RSV season (October-April). The main question it aims to answer is: * What is the prevalence of RSV infection in patients with COPD during exacerbations in the RSV season? * Does RSV infection lead to worse clinical outcomes, including hospitalization, longer length of stay, acute cardiovascular events, and/or death in patients with COPD exacerbations? Researchers will compare patients with RSV infection to those without RSV infection to see if RSV infection results in worse clinical outcomes, such as increased hospitalization, longer stays, cardiovascular events, or death. Participants will: * Be adults diagnosed with COPD who present to the emergency department or day hospital due to acute exacerbations of their respiratory symptoms. * Receive treatment as per standard clinical care for COPD exacerbations, including long-acting bronchodilators and inhaled corticosteroids, and may complete a course of antibiotics and/or oral corticosteroids if prescribed during hospitalization. * Undergo diagnostic testing for RSV infection as part of the clinical routine to determine the presence or absence of the virus during their exacerbation. * Have clinical outcomes monitored, including hospitalization rate, length of stay, and any acute cardiovascular events, as well as mortality during the exacerbation period. * Provide relevant demographic and clinical data, including medical history, COPD severity, comorbidities, and previous exacerbation events.


Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This study (RECODE) is investigating how often respiratory syncytial virus (RSV) — a common respiratory virus — triggers flare-ups (exacerbations) of chronic obstructive pulmonary disease (COPD), a lung condition that makes breathing difficult. **You may be eligible if...** - You are 50 years of age or older (any gender) - You are seeking urgent medical care because of a COPD flare-up (worsening shortness of breath and/or cough and mucus lasting less than 14 days) **You may NOT be eligible if...** - You have previously received an RSV vaccine - You have active cancer or are currently being treated for cancer - Other health conditions make participation unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Hospital Clínic de Barcelona

Barcelona, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06735612


Related Trials